MORETTINI, ALESSANDRO
 Distribuzione geografica
Continente #
EU - Europa 429
NA - Nord America 369
AS - Asia 137
OC - Oceania 7
SA - Sud America 1
Totale 943
Nazione #
US - Stati Uniti d'America 369
RU - Federazione Russa 224
IT - Italia 98
CN - Cina 42
HK - Hong Kong 33
IE - Irlanda 30
SG - Singapore 28
SE - Svezia 24
CH - Svizzera 13
DE - Germania 12
FI - Finlandia 11
IN - India 11
JO - Giordania 11
NL - Olanda 9
AU - Australia 7
ID - Indonesia 7
KR - Corea 3
GB - Regno Unito 2
TR - Turchia 2
AT - Austria 1
BE - Belgio 1
BG - Bulgaria 1
BR - Brasile 1
FR - Francia 1
GR - Grecia 1
UA - Ucraina 1
Totale 943
Città #
Santa Clara 157
Dublin 30
Ashburn 29
Chandler 27
Singapore 26
Hong Kong 25
Florence 20
Moscow 20
Fairfield 18
Bern 13
Amsterdam 8
Houston 8
Mumbai 8
Helsinki 7
Jakarta 7
Shanghai 7
Altamura 6
Boardman 6
Kent 6
Lawrence 6
Melbourne 6
Sant'elpidio A Mare 6
Siena 6
Princeton 5
Buffalo 4
Cambridge 4
Falkenstein 4
Lappeenranta 4
Napoli 4
New York 4
Washington 4
Wilmington 4
Woodbridge 4
Ann Arbor 3
Boston 3
Chengdu 3
Rome 3
Seoul 3
Yubileyny 3
Avellino 2
Beijing 2
Bremen 2
Campi Bisenzio 2
Campomorone 2
Chicago 2
Frankfurt am Main 2
Fucecchio 2
Imola 2
Los Angeles 2
Medford 2
Nashik 2
Pisa 2
San Diego 2
San Francisco 2
San Giovanni Valdarno 2
San Jose 2
Abenberg 1
Andover 1
Athens 1
Baoding 1
Bologna 1
Brussels 1
Catanzaro 1
Cedar Knolls 1
Changsha 1
Guangzhou 1
Hangzhou 1
Jacksonville 1
Jiangmen 1
Jiaxing 1
Karur 1
Le Havre 1
Leawood 1
London 1
Ma'anshan 1
Milan 1
Monteriggioni 1
Munich 1
Nagold 1
Nanjing 1
Nanyang 1
Norwalk 1
Prescot 1
Scandicci 1
Scarperia e San Piero 1
Seattle 1
Shenyang 1
Specchia 1
Sydney 1
São Paulo 1
Taiyuan 1
Vienna 1
Wenzhou 1
Totale 582
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 132
Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients 124
Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy 95
Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS‑CoV‑2 disease 88
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection 86
Careggi Re-Engineered Discharge project: standardize discharge and improve care coordination between healthcare professionals 84
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 78
SSRIs in the course of COVID-19 pneumonia: Evidence of effectiveness of antidepressants on acute inflammation. A retrospective study 64
Doubts and concerns about COVID-19 uncertainties on imaging data, clinical score, and outcomes 63
Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19 62
Effectiveness of tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real-life study 49
Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19 38
Totale 963
Categoria #
all - tutte 4.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.607


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202176 0 0 21 15 8 2 1 11 3 2 8 5
2021/202247 4 1 0 2 5 4 2 4 3 1 9 12
2022/2023160 9 28 10 7 15 29 20 7 19 2 1 13
2023/2024178 3 10 12 8 7 18 8 51 11 13 18 19
2024/2025502 21 61 44 152 151 73 0 0 0 0 0 0
Totale 963